Abstract 265 Table 2 Results of chi-square tests comparing premature ovarian failure (POF) prevalence with different chemotherapy schedules. OR: odds ratio; CI: confidence intervals; TaxAC-CMF: Anthracycline and taxane – cyclophosphamide, methotrexate, and fluorouracil; VAI/AI: vincristine, adriamycin and ifosfamide/adriamycin and ifosfamide; EPI-IFO: epirubicin and ifosfamide; ABVD: adriamycin, bleomycine, vinblastine and doxorubicin; CHOP: cyclophosphamide, doxorubicin, vincristine and prednisone; FEC: fluorouracil, epirubicine and cyclophosphamide; BEACOPP: bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone

Schedule	POF prevalence	OR (95% CI)	p-value
Platinum-based	8/24 (33%)	1.6 (0.6 – 4)	ns
TaxAC-CMF	7/18 (39%)	2.0 (0.7 – 5.7)	ns
VAI/AI	2/8 (25%)	1 (0.1 – 5.1)	ns
EPI-IFO	9/19 (47%)	3.1 (1.1 – 8.2)	0.02
Capecitabine	3/4 (75%)	9.5 (0.9 – 94.4)	0.04
ABVD	2/41 (4.9%)	0.1 (0.02 – 0.4)	0.0001
CHOP	8/13 (62%)	5.6 (1.7 – 18.2)	0.004
FEC + weekly paclitaxel	3/16 (19%)	0.6 (0.1 – 2.4)	ns
Oncocarbide	0/4 (0%)	0.7 (0.6 – 0.8)	ns
Fludarabine	1/3 (33%)	1.5 (0.1 – 17.0)	ns
BEACOPP	3/5 (60%)	4.7 (0.7 – 29.3)	0.09
Temozolomide	2/7 (29%)	1.2 (0.2 – 6.4)	ns
Monoclonal antibody	8/24 (33%)	1.6 (0.6 – 4)	ns
Trabectedin	1/5 (20%)	0.7 (0.08 – 6.8)	ns
High-dose	22/24 (94%)	63.6 (14 – 289)	0.0001

at cancer diagnosis and with every change of treatment. This has a very important implication: the necessity to implement fertility preservation strategies when the risk increases.

290

THE IMPACT OF A NATIONAL MULTIDISCIPLINARY TUMOR BOARD FOR CANCER DURING PREGNANCY

^{1,2}J Heimovaara*, ³IA Boere, ⁴J De Haan, ^{5,6}K Van Calsteren, ^{1,2,7}F Amant, ⁸L Van Zuylen, ^{2,7}C Lok*. ¹KU Leuven, Department of Oncology, Leuven, Belgium; ²The Netherlands Cancer Institute (NKI) – Antoni van Leeuwenhoek, Department of Gynaecology, Amsterdam, Netherlands; ³Erasmus MC Cancer Institute, Erasmus University Medical Center, Department of Medical Oncology, Rotterdam, Netherlands; ⁴Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Department of Obstetrics and Gynaecology, Amsterdam, Netherlands; ⁵University Hospital Leuven, Department of Obstetrics and Gynaecology, Leuven, Belgium; ⁶KU Leuven, Department of Development and Regeneration, Leuven, Belgium; ⁷Antoni van Leeuwenhoek, Center for Gynaecological Oncology Amsterdam (CGOA), Amsterdam, Netherlands; ⁸Amsterdam University Medical Centers, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Department of Medical Oncology, Amsterdam, Netherlands

10.1136/ijgc-2021-ESGO.238

Introduction/Background* Physicians encounter pregnant women with cancer only incidentally, leading to lack of expertise or confidence to inform and treat these patients according to up to date guidelines and expert opinions. In the Netherlands, a national multidisciplinary tumor board (MDT) for cancer and pregnancy was founded in 2012, and consists of 33 physicians from all over the country. Requests to discuss patients in the MDT were received by e-mail and a recommendation letter was generated based on available literature and expert opinion of the board members.

Methodology All requests and recommendations were gathered in a database and analyzed for tumor type, stage, gestational age and recommendation given. A survey was sent out to 93 physicians who requested recommendations of the MDT, containing questions regarding their experiences with the MDT and the impact on treatment decisions.

Result(s)* From December 2012 to May 2021, 209 recommendations were formulated, mostly regarding pregnant

Abstract 290 Figure 1

patients with breast cancer (n=65), cervical cancer (n=32), haematological malignancies (n= 32), rare cancer types (n=30) and melanoma (n=21). Questions were asked regarding possibilities of ionized imaging, chemotherapy, hormonal therapy or immunotherapy during pregnancy and possible effects on the child, the sequence of the different treatment components and questions on fertility. Response rate of the questionnaire was 54%. Overall satisfaction with the recommendations of the MDT was high, and 94% of the respondents informed their patients about consulting the MDT and felt supported by the received recommendations.

Conclusion* A national MDT for cancer and pregnancy is frequently consulted and highly appreciated by physicians. Next to that, it increases expertise of its members about this rare coincidence of cancer and pregnancy. We highly recommend to establish an (inter)national MDT in each country. Figure 1 shows the important steps necessary to establish an MDT for cancer in pregnancy based on our experience.

324 COMPARISON OF SERUM HE4 AND CA125 LEVELS IN THE EARLY POSTPARTUM PERIOD

¹R Delic*, ²M Stefanovic, ³S Krivec, ¹J Koren. ¹General and Teaching Hospital Celje, Department of Gynecology and Obstetrics, Celje, Slovenia; ²Sestre milosrdnice University Hospital Center, Department of Clinical Chemistry, Zagreb, Croatia; ³General and Teaching Hospital Celje, Department of Laboratory Medicine, Celje, Slovenia

10.1136/ijgc-2021-ESGO.239

Introduction/Background* This study was undertaken to evaluate and compare CA125 and HE4 serum concentrations in the early postpartum period.

Methodology In a prospective designed, monocentric study (Department of Gynecology & Obstetrics, General and Teaching Hospital, Celje, Slovenia, EU), 68 women who were in the 1-3rd day of postpartum period were included in the study.

HE4 and CA125 levels were obtained and analysed with regard to each day of postpartum period (1st, 2nd and 3rd day after delivery) as well as regarding the method of delivery (vaginal delivery; n=46, elective (EICS); n=15 and emergency caesarean section (EmCS); n=8).

CA125 and HE4 levels were measured in consideration of their reference intervals less than 35 IU/ml and less than 140 pmol/l, respectively (Elecys CA 125 II[®] assay and Elecys HE4[®] assay, Roche Diagnostics Ltd., Rotkreuz, Switzerland).

Data were analysed by ANOVA (MedCalc Software, Maria-kerke, Belgium).

Result(s)* The CA-125 levels were frequently above the conventional cut-off limit of 35 IU/mL; differences in mean concentrations between study groups were not found to be statistically significant (Group I, n=44, 1st day after delivery, mean = 39,4 IU/ml; Group II, n = 19, 2nd day after delivery, mean = 32,8 IU/ml; Group III, n =5, 3rd day after delivery, mean = 38,8 IU/ml, p = 0,708).

Regarding the method of delivery, women in the vaginal delivery group had seemingly higher levels of CA125 than the women in both caesarean section groups, but still not statistically significant (44,0 IU/ml vs 29,7 IU/ml (EICS) and 21,5 IU/ml (EmCS), respectively; p=0,057).

HE4 levels were within reference range and significant difference was also not observed between 1st, 2nd and 3rd day postpartum (Group I, n=44, 1st day after delivery, mean = 60,3 pmol/l; Group II, n = 19, 2nd day after delivery, mean

Abstract 324 Figure 1

Abstract 324 Figure 2

= 54,3 pmol/l; Group III, n =5, 3rd day after delivery, mean = 49,2 pmol/l, p = 0,096).

Regarding the method of delivery, women in the vaginal delivery group had significantly lower levels of HE4 than the women in both caesarean section groups (54,5 pmol/l vs 65,7 pmol/l (EICS) and 61,1 pmol/l (EmCS), respectively; p=0,015).

Conclusion* According to our preliminary results, HE4 is more reliable marker of malignancy during the early postpartum period than CA125.

348 CONSERVATIVE SURGERY AND OVERALL SURVIVAL IN YOUNG WOMEN WITH A DIAGNOSIS OF BORDERLINE OVARIAN TUMOR

M Laseca Modrego*, O Arencibia Sanchez, D González García-Cano, AF Rave Ramirez, A Martín Martínez. Maternal Child Hospital of the Canary Islands, Oncology Gynecology Department, Las Palmas de Gran Canaria, Spain

10.1136/ijgc-2021-ESGO.240

Introduction/Background* Radical surgery is the main treatment for Borderline Ovarian Tumors. Surgery includes hysterectomy, double adnexectomy, omentectomy and appendectomy if the histological line is mucinous.